Clinical Trial: NCT03075423
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Goethe University |
| Information Provided By: | Goethe University |
| Last Update Posted: | 2025-09-26 |
Study Overview
Brief Summary
SUNNIFORECAST (Standard of Care vs. Nivolumab + Ipilimumab as First line treatment of renal cell cancer of non-clear cell subtypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab (BMS-936558) combined with Ipilimumab vs standard of care in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma (nccRCC).
Official Title
Conditions
Intervention / Treatment
- Drug: Ipilimumab plus nivolumab
- Drug: Standard Therapy
Other Study ID Numbers
- SUNNIFORECAST
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Goethe University |
| Information Provided By: | Goethe University |
| Last Update Posted: | 2025-09-26 |
Study Overview
Brief Summary
SUNNIFORECAST (Standard of Care vs. Nivolumab + Ipilimumab as First line treatment of renal cell cancer of non-clear cell subtypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab (BMS-936558) combined with Ipilimumab vs standard of care in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma (nccRCC).
Official Title
Conditions
Intervention / Treatment
- Drug: Ipilimumab plus nivolumab
- Drug: Standard Therapy
Other Study ID Numbers
- SUNNIFORECAST